You are on page 1of 2

MINUTES OF A SPECIAL MEETING

OFTHE

BOARD OF DIRECTORS

OF

LAIDLAW & COMPANY (UK) LTD.

Dated: March 6, 2017

A meeting of the Board of Directors (the "Board") of Laidlaw & Company (UK) Ltd., a
(the "Company"), was held on March 6, 2017 at approximately 10:00 a.m. EDT (the "Meeting")
at the Company's offices in New York, New York. Participating in person were Matthew Bitner
and James Ahern.

Mr. Bitner declared a quorum present, called the Meeting to order and presided over the
Meeting. Both Messrs. Eitner and Ahern each agreed that they waive any requirement for notice
of this meeting of the Board and that such shall be entered into the minute book of the Company.

Mr. Eitner began the meeting with a general summary of the terms of the proposed
temporary subordinated loan to the Company in the aggregate principal amount of $3,000,000
(the " Sub Loan"), in order to facilitate its underwriting of a firm commitment initial public
offering of Therapix Biosciences Ltd., a security to be listed on the NASDAQ Capital Market.

Following discussion, and upon motion duly made and seconded, the following
resolutions were adopted by the Board of Directors:

WHEREAS, in the judgment of the Board of Directors of the Company, it has been
determined that the Company should accept the temporary subordinated loan
evidenced by the temporary subordinated agreements in aggregate amount of
$3,000,000 from HS Contrarian Investments, LLC (the "Sub Loan") in order to
facilitate the firm's participation as a lead manager in the firm commitment
initial public offering of Therapix Biosciences Ltd. in the approximate amount of
$30,000,000.

NOW, THEREFORE BE IT RESOLVED, the Board of Directors agrees to accept Sub


Loan in aggregate amount of $3,000,000 from HS Contrarian Investments, LLC,
in order to facilitate the firm's participation as a lead manager in the firm
commitment initial public offering of Therapix Biosciences Ltd. in the
approximate amount of $30,000,000; and it is further

RESOLVED, that the form, terms and provisions of the documents evidencing the Sub
Loan, in substantially the form attached hereto as Exhibit A (the "Sub Loan
Agreements"), be, and the same hereby is, ratified, authorized and approved in

SMRH:226256410.2 -1-
all respects, and that the Company is hereby authorized to perform its obligations
under the Sub Loan Agreements, and that the authorized officers of the
Company, be, and each of them hereby is, authorized, in the name and on behalf
of the Company and under its corporate seal or otherwise, to execute and deliver
the Sub Loan Agreements, with such changes therein as the officer executing the
same shall approve, such approval to be conclusively evidenced by his execution
thereof; and it is further

RESOLVED, that the authorized officers be, and each of them with full authority to act
without the others hereby is, authorized and directed for and on behalf of the
Company to take or cause to be taken any and all actions, to execute and deliver
any and all certificates, instructions, requests, or other instruments, and to do any
and all things which, in any such officer's judgment, may be necessary or
desirable to effect each of the foregoing resolutions and to carry out the purposes
thereof, the taking of any such actions, the execution and delivery of any such
certificates, instructions, requests, or instruments, or the doing of any such things
to be conclusive evidence of their necessity or desirability; and it is further

RESOLVED, that the "authorized officers" of the Company shall mean the Chairman,
Chief Executive Officer, the President or any Vice President, the Treasurer or any
Assistant Treasurer, and the Secretary or any Assistant Secretary; and it is further

RESOLVED, that, any actions taken by such officers prior to the date of the foregoing
resolutions adopted hereby, that are within the authority conferred thereby, are
hereby ratified, confirmed and approved as the acts and deeds of the Company.

There being no further business to come before the meeting, upon motion duly made and
seconded, the meeting was adjourned at approximately 10: 15 am.

Respectfully submitted,

Matthew Eitner, Director

James Ahem, Director

SMRH:226256410.2 -2-